• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
DENG Wu-sheng,SUN Jie.Research progress on the treatment after resistance to first generation EGFR-TKI in patients with non-small cell lung cancer[J].Journal Of Pharmaceutical Research,2015,34(12):722-725,740[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3338times   Download 3818次 QR Code for this article
Scan with your phone!
非小细胞肺癌第一代EGFR-TKI耐药后的治疗进展
邓务生,孙杰
Font:Larger+|Default|Smaller-
(广东医学院附属医院呼吸内科,广东 湛江 524001)
摘要:
肺癌是世界上最常见的恶性肿瘤,严重威胁着人们的生命健康。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)已成为非小细胞肺癌的研究热点。表皮生长因子受体酪氨酸激酶抑制剂为表皮生长因子受体基因突变患者的首选治疗方案,可用于非小细胞肺癌的一线治疗、二线治疗以及维持治疗。但随着疾病的进展,肿瘤不可避免产生耐药,从而导致治疗失败。本文就非小细胞肺癌第一代表皮生长因子受体酪氨酸激酶抑制剂耐药后的治疗作一综述。
关键词:  非小细胞肺癌  耐药  表皮生长因子受体  酪氨酸激酶抑制剂
DOI:10.13506/j.cnki.jpr.2015.12.012
基金项目:广东省科技计划项目(No.2011B031800343)
Research progress on the treatment after resistance to first generation EGFR-TKI in patients with non-small cell lung cancer
DENG Wu-sheng,SUN Jie
(Department of Respiratory Medicine,Affiliated Hospital of Guangdong Medical College,Zhanjiang 524001,China)
Abstract:
Lung cancer is one of the most common malignant tumors in the world and a serious threat to human health.EGFR-TKI has become the hot topic in Non-small cell lung cancer.EGFR-TKI is the first-line treatmen on EGFR gene mutations in lung cancer,EGFR-TKI has been used for first-line therapy, second-line treatment and maintenance therapy in Non-small cell lung cancer. Although the results of EGFR-TKI for patients with Non-small cell lung cancer has been effective, with the progression of the disease,it inevitably may lead to durg resistance.In this paper,we made a review on the treatment after resistance to first generation EGFR-TKI in patients with Non-small cell lung cancer.
Key words:  Non-small cell lung cancer  Resistance  EGFR  EGFR-TKI
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.